Blood
Articles in this Issue
Electronic heath record phenotypes to classify sickle cell anemia versus other subtypes of sickle cell disease in the ASH RC data hub
Abstract Introduction: Sickle cell disease (SCD) comprises a group of severe hemoglobinopathies caused by mutations in the β-globin gene (HB...
Evaluation of current diagnostic workup for pediatric severe aplastic anemia: Low incidence of cryptic inherited bone marrow failure syndromes
Abstract Background:Pediatric severe aplastic anemia (SAA) is a rare diagnosis characterized by pancytopenia with a hypocellular bone marrow...
Monte Carlo simulation of HLA-DQ heterodimers and their interactions to predict relapse and GVHD risk in cord blood transplantation
Abstract Background The importance of HLA-DQ heterodimers on outcomes in unrelated and haploidentical stem cell transpla...
Modeling del(17p) in multiple myeloma for molecular and functional characterization
Abstract Multiple myeloma (MM) remains a challenging hematological malignancy, with outcomes varying widely due to genetic heterogeneity. Am...
Single-day non-activated IL-18-armed CAR T cells with enhanced persistence and durable efficacy
Abstract Background: Chimeric antigen receptor (CAR) T cell therapies have transformed the treatment of B-cell malignancies, yet challenges...
Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient characteristics and outcomes research (Real-EPCOR) study
Abstract Introduction: Epcoritamab (epcor) was the first CD3xCD20 bispecific antibody approved for treatment of R/R DLBCL in May 2023 based...
Azacitidine-panobinostat activates NF-kb signaling in the bone marrow microenvironment to chemosensitize KMT2A rearranged pediatric AML
Abstract KMT2A rearrangements (KMT2Ar), a hallmark of pediatric acute leukemia, are present in 20% of pediatric acute myeloid leukemia (AML)...
Determinants of survival in primary plasma cell leukemia (PPCL): Analysis of a real-world pooled database
Abstract Background: Primary plasma cell leukemia (PPCL) is a rare and highly aggressive form of plasma cell dyscrasia,...
An open label randomized Study of low dose dasatinib (50 mg OD) vs standard dose dasatinib (100 mg OD) vs standard dose imatinib (400 mg OD) as upfront therapy in patients with newly diagnosed chronic myeloid leukemia (CML) - chronic Phase (CP)
Abstract The use of tyrosine kinase inhibitors (TKIs) in CML CP has extended survival to a near-normal life expectancy. The concept of ‘opti...
The treatment of transplant eligible primary plasmacell leukemia patients: An italian real-life Study
Abstract Primary plasma cell leukemia (pPCL) is a rare variant of plasma cell malignancy characterized by at least 5% of circulating plasma...
Multi-omic spatial profiling of EBV+ hodgkinoid lymphoproliferation reveals divergent biological features and novel diagnostic biomarkers.
Abstract Background: Epstein-Barr virus (EBV)-positive lymphoproliferative disorders can exhibit overlapping Hodgkin-like morphological feat...
Novel multifunctional degraders of EP300/CBP and IKZF1/3 with potent anti-myeloma activity
Abstract Immunomodulatory imide drugs (IMiDs) are well-established therapies for patients with multiple myeloma (MM) (Hartley-Brown 2024). T...
Real-world healthcare resource utilization (HCRU) following CAR T-cell therapy in US patients treated in newly authorized treatment centers
Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy offers significant benefits for patients with lymphoid malignancies, a...
Prototype evaluation of a digital quality of life tracker for patients (pts) with chronic myeloid leukemia (CML) to inform pt-provider conversations
Abstract Introduction Maintaining good quality of life (QOL) is a key consideration for pts with CML, yet there remains a lack of clarity an...
Clinical implications of epigenetic age acceleration as a novel biomarker in Acute Myeloid Leukemia
Abstract Background: Building on our first-generation epigenetic clock, we now present an enhanced approach to capture biological aging proc...
Multiplex base editing enhances fetal hemoglobin production in sickle cell disease erythroid cells
Abstract Base editing offers a powerful platform for precise, scarless genome modification without introducing DNA double-strand breaks. Her...
VIP, a novel phagocytosis checkpoint in TP53-mutated Acute Myeloid Leukemia
Abstract Background: Acute myeloid leukemia (AML) remains one of the most lethal hematologic malignancies, particularly in elderly patients a...
Surzetoclax (ABBV-453) in combination with daratumumab and dexamethasone in biomarker-selected patients with Relapsed/Refractory multiple myeloma: A Phase 1/2, multicenter, open-label platform study
Abstract Background and Significance: Multiple myeloma (MM) is a plasma cell malignancy with complex cytogenetic abnormalities that contribu...
Developing artificial intelligence-based transcriptomic signature for the diagnosis of dark zone lymphoma in patients without MYC gene rearrangement
Abstract Introduction: Double hit diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) are currently defined as dark zone lymphoma...
Gold salt phospholipid inhibits glutathione peroxidase 4 (GPx4) and causes cell death in Mantle Cell Lymphoma: Demonstration of single agent activity and synergy with ibrutinib
Abstract Introduction: Bruton's tyrosine kinase (BTK) inhibitors (BTKi), such as ibrutinib, have become the standard of care for mantle cell...
Evaluating the management of severe anemia in the emergency department: A single-center analysis
Abstract Introduction: Severe anemia is commonly encountered in emergency departments (EDs), often prompting red blood cell (RBC) transfusio...
Melphalan weight-based dosing in overweight and obese patients undergoing autologous transplant for multiple myeloma
Abstract Introduction: Over one-third of Americans are obese, yet guidance on chemotherapy dosing in this group is scarce. Melphalan remains...
CD15 expression on leukemic cells associates with extramedullary infiltration and adverse outcomes in Acute Myeloid Leukemia
Abstract Objectives: We characterized CD15 expression on leukemic cells across newly diagnosed, relapsed/refractory, and extramedullary-infi...
Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): First Results from part 1 of the Phase 3 Olympia-3 study
Abstract Introduction Odronextamab (Odro), a CD20×CD3 bispecific antibody, has shown compelling efficacy as monotherapy...
Long-term outcomes of patients with hairy cell leukemia treated with first-line cladribine in British Columbia
Abstract Background Hairy cell leukemia (HCL) is a rare indolent B-cell malignancy. First-line (1L) treatment typically includes a purine an...